Study was never initiated due to company decision. No study subjects were ever enrolled or dosed.

This study will investigate the pharmacokinetics, safety and tolerability of dapsone and adapalene following topical administration of 2 formulations of dapsone/adapalene fixed combination gel, dapsone 5% gel (ACZONE®), and adapalene 0.3% gel (Differin®) in subjects with acne vulgaris.

Inclusion Criteria:

• Moderate acne on the face
• Willing to avoid swimming during the study
• Willing to avoid excessive sunlight and ultraviolet light (e.g., tanning beds)during the study
• Willing to avoid moisturizers, sunscreens, cosmetics, and chemical peels during the study

Exclusion Criteria:

• Severe cystic acne
• Use of topical or oral retinoids within 4 weeks
• Use of isotretinoin within 3 months
• Use of dapsone or adapalene within 3 months
• Anticipated need to engage in activities/exercise that would cause profuse sweating
• Donated blood or equivalent blood loss within 90 days